129.74USD+2.84%Mkt Cap: —P/E: 30.891d ago
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment o…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value20.72B $
Revenue (TTM)5.82B $
Gross Profit3.24B $
Net Income (TTM)1.61B $
Revenue/Share29.36 USD
Last Price129.74 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.8K
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINUS45337C1027
Valuation
P/E (Trailing)30.89
P/E (Forward)—
PEG—
EV/EBITDA10.67
EV/Revenue3.56
P/S—
P/B3.92
EPS (TTM)4.20
EPS (Forward)—
52W Range
121.3097% of range130.00
52W High130.00 USD
52W Low121.30 USD
Profitability
Gross Margin55.66%
Oper. Margin41.90%
EBITDA Margin33.38%
Profit Margin27.71%
ROE30.67%
ROA16.83%
Growth
Revenue Growth37.70%
Earnings Growth37.70%
Cash Flow & Leverage
Operating CF1.98B $
CapEx (TTM)—
FCF Margin20.29%
FCF Yield—
Net Debt-4.50B $
Net Debt/EBITDA-2.32
Balance Sheet
Debt/Equity0.60
Current Ratio4.59
Quick Ratio4.31
Book Value/Sh31.57 USD
Cash/Share22.38 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.212.81M
Float170.73M
Insiders1.84%
Institutions103.82%
Technical
SMA 5060.56 (+114.2%)
SMA 20060.39 (+114.8%)
Beta0.77
S&P 52W Chg20.80%
Avg Vol (30d)678
Avg Vol (10d)1.37K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—